Last reviewed · How we verify
Niemann-Pick disease, type C — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zavesca | MIGLUSTAT | AstraZeneca | Glucosylceramide Synthase Inhibitor [EPC] | Lysosomal alpha-glucosidase | 2003-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- AstraZeneca · 1 drug in Niemann-Pick disease, type C
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Niemann-Pick disease, type C:
- Niemann-Pick disease, type C treatment updates — RSS
- Niemann-Pick disease, type C treatment updates — Atom
- Niemann-Pick disease, type C treatment updates — JSON
Cite this brief
Drug Landscape (2026). Niemann-Pick disease, type C — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/niemann-pick-disease-type-c. Accessed 2026-06-10.
Related
- Niemann-Pick disease, type C full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing